Journal of Managed Care & Specialty Pharmacy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 11
Published: Dec. 20, 2024
is
a
health
system
and
policy
goal
of
ensuring
equitable
access
to
high-quality
medications
for
all
individuals,
regardless
factors
such
as
race,
ethnicity,
socioeconomic
status,
or
resource
availability
reduce
disparities.
Although
measurement
frameworks
have
been
widely
used
in
equity
contexts,
focused
framework
pharmacoequity
remains
critical
gap.
In
this
article,
we
introduce
novel
anchored
the
patient
medication-use
journey.
The
includes
following
domains:
(1)
care
services,
(2)
prescription
generation,
(3)
primary
medication
nonadherence,
(4)
secondary
(5)
monitoring.
For
each
domain,
provide
examples
outcome
measures
potential
data
sources
that
can
be
evaluation.
We
also
outline
an
implementation
workflow
population
stakeholders
use
across
various
settings
(eg,
systems,
plans).
provides
structured
approach
identify
existing
gaps
path
toward
achieving
lay
foundation
targeted
interventions.
Additionally,
it
enables
ongoing
monitoring
progress
while
identifying
interventions
are
effective,
scalable,
sustainable.
Summary
Background
The
current
obesity
pandemic
has
given
rise
to
associated
comorbidities
and
complications,
including
type
2
diabetes
metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD).
During
the
last
decade,
certain
glucagon‐like
peptide
1
receptor
agonists
(GLP‐1RA),
originally
developed
as
antihyperglycemic
drugs,
also
demonstrated
efficacy
for
weight
loss.
Aims
To
review
shared
pathophysiologic
features
of
common
diseases
compare
therapeutic
strategies
reduce
body
related
complications.
Methods
We
performed
an
extensive
literature
research
describe
effects
lifestyle
modification,
first‐generation
anti‐obesity
GLP‐1RA
on
loss
in
humans
with
obesity,
MASLD.
Results
Until
recently,
treatment
been
limited
which
offer
moderate
degree
sustainability
few
approved
drugs
are
either
short
term
use
or
forms
obesity.
Some
significantly
decrease
caloric
intake
weight.
Liraglutide
semaglutide
have
therefore
treating
people
They
lead
a
reduction
hepatic
fat
content
inflammation
biopsy‐confirmed
Possible
limitations
comprise
adverse
effects,
adherence
persistence.
Conclusion
Certain
superior
modification
inducing
markedly
changed
portfolio
additional
beneficial
disease.
Diabetes Care,
Journal Year:
2024,
Volume and Issue:
48(Supplement_1), P. S14 - S26
Published: Dec. 9, 2024
The
American
Diabetes
Association
(ADA)
“Standards
of
Care
in
Diabetes”
includes
the
ADA’s
current
clinical
practice
recommendations
and
is
intended
to
provide
components
diabetes
care,
general
treatment
goals
guidelines,
tools
evaluate
quality
care.
Members
ADA
Professional
Practice
Committee,
an
interprofessional
expert
committee,
are
responsible
for
updating
Standards
annually,
or
more
frequently
as
warranted.
For
a
detailed
description
standards,
statements,
reports,
well
evidence-grading
system
full
list
Committee
members,
please
refer
Introduction
Methodology.
Readers
who
wish
comment
on
invited
do
so
at
professional.diabetes.org/SOC.
JAMA Network Open,
Journal Year:
2023,
Volume and Issue:
6(12), P. e2347519 - e2347519
Published: Dec. 14, 2023
Importance
Medication
nonadherence
is
common
among
patients
with
heart
failure
reduced
ejection
fraction
(HFrEF)
and
can
lead
to
increased
hospitalization
mortality.
Patients
living
in
socioeconomically
disadvantaged
areas
may
be
at
greater
risk
for
medication
due
barriers
such
as
lower
access
transportation
or
pharmacies.
Objective
To
examine
the
association
between
neighborhood-level
socioeconomic
status
(nSES)
HFrEF
assess
mediating
roles
of
transportation,
walkability,
pharmacy
density.
Design,
Setting,
Participants
This
retrospective
cohort
study
was
conducted
June
30,
2020,
December
31,
2021,
a
large
health
system
based
primarily
New
York
City
surrounding
areas.
Adult
diagnosis
HF,
EF
on
echocardiogram,
prescription
least
1
guideline-directed
medical
therapy
(GDMT)
were
included.
Exposure
Patient
addresses
geocoded,
nSES
calculated
using
Agency
Healthcare
Research
Quality
SES
index,
which
combines
census-tract
level
measures
poverty,
rent
burden,
unemployment,
crowding,
home
value,
education,
higher
values
indicating
nSES.
Main
Outcomes
Measures
obtained
through
linkage
record
data
fill
defined
proportion
days
covered
(PDC)
less
than
80%
over
6
months,
averaged
across
GDMT
medications.
Results
Among
6247
patients,
mean
(SD)
age
73
(14)
years,
majority
male
(4340
[69.5%]).
There
1011
(16.2%)
Black
participants,
735
(11.8%)
Hispanic/Latinx
3929
(62.9%)
White
participants.
had
rates
nonadherence,
ranging
from
51.7%
lowest
quartile
(731
1086
participants)
40.0%
highest
(563
(
P
<
.001).
In
adjusted
analysis,
2
quartiles
significantly
odds
when
compared
(quartile
1:
ratio
[OR],
1.57
[95%
CI,
1.35-1.83];
2:
OR,
1.35
1.16-1.56]).
No
mediation
by
density
found,
but
small
amount
neighborhood
walkability
observed.
Conclusions
Relevance
this
HFrEF,
area
associated
nonadherence.
These
findings
highlight
importance
considering
disparities
developing
approaches
improve
adherence.
Expert Opinion on Drug Safety,
Journal Year:
2024,
Volume and Issue:
23(7), P. 797 - 810
Published: May 13, 2024
Patients
with
type
2
diabetes
(T2DM)
are
at
high
risk
of
atherosclerotic
cardiovascular
disease
(ASCVD)
and
death.
Cardiovascular
protection
is
a
key
objective
in
T2DM.
Journal of Managed Care & Specialty Pharmacy,
Journal Year:
2025,
Volume and Issue:
31(2), P. 214 - 224
Published: Feb. 1, 2025
Pharmacoequity
is
a
health
system
and
policy
goal
of
ensuring
equitable
access
to
high-quality
medications
for
all
individuals,
regardless
factors
such
as
race,
ethnicity,
socioeconomic
status,
or
resource
availability
reduce
disparities.
Although
measurement
frameworks
have
been
widely
used
in
equity
contexts,
focused
framework
pharmacoequity
remains
critical
gap.
In
this
article,
we
introduce
novel
anchored
the
patient
medication-use
journey.
The
includes
following
domains:
(1)
care
services,
(2)
prescription
generation,
(3)
primary
medication
nonadherence,
(4)
secondary
(5)
monitoring.
For
each
domain,
provide
examples
outcome
measures
potential
data
sources
that
can
be
evaluation.
We
also
outline
an
implementation
workflow
population
stakeholders
use
across
various
settings
(eg,
systems,
plans).
provides
structured
approach
identify
existing
gaps
path
toward
achieving
lay
foundation
targeted
interventions.
Additionally,
it
enables
ongoing
monitoring
progress
while
identifying
interventions
are
effective,
scalable,
sustainable.
Alzheimer s & Dementia,
Journal Year:
2025,
Volume and Issue:
21(4)
Published: April 1, 2025
Abstract
INTRODUCTION
Both
the
advance
care
planning
(ACP)
visit
and
cognitive
assessment
service
(CAACPS)
offer
palliative‐oriented
for
persons
with
Alzheimer's
disease
related
dementias
(ADRD);
however,
rate
of
ACP
visits
remains
low,
little
has
been
reported
regarding
CAACPS
visits.
Furthermore,
few
reports
describe
use
either
among
Medicare
Advantage
(MA)
beneficiaries.
This
study
describes
provision
to
community‐dwelling
older
adult
MA
beneficiaries
ADRD.
METHODS
Using
deidentified
Optum
Clinformatics
Data
Mart
claims
data,
we
evaluated
ambulatory
ADRD
years
2018
2019.
RESULTS
For
2019,
3.5%
5.4%
received
visits,
0.4%
0.5%
similar
elsewhere.
DISCUSSION
Few
or
delivery
CAACPs
is
that
non‐MA
Highlights
Most
dementia
are
disproportionately
disadvantaged.
Access
palliative
limited
dementia.
may
address
this
gap.
Our
findings
show
very
low.
